Payment overview · 2025
General Payments
$933.05
46 reported records · 15 companies
Healthcare provider profile · identity verified
Irit Hemed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1255398665
Verified facts
What the public records show
CMS Open Payments records show Irit Hemed, MD received $933.05 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $335.48 | 36.0% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $111.19 | 11.9% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $78.15 | 8.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.18 | 8.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.96 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.14 | 5.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.68 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.51 | 4.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.17 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.79 | 2.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.09 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.34 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.34 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.72 | 1.7% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.31 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $933.05 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $162.81 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $111.19 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.29 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.75 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $78.15 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.68 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
137 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 877 | 249 |
| Levothyroxine Sodium | Levothyroxine Sodium | 655 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 161 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 141 |
| Losartan Potassium | Losartan Potassium | 467 | 129 |
| Hydrochlorothiazide | Hydrochlorothiazide | 341 | 97 |
| Methylprednisolone | Methylprednisolone | 300 | 221 |
| Lisinopril | Lisinopril | 266 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 68 |
| Simvastatin | Simvastatin | 231 | 61 |
| Omeprazole | Omeprazole | 229 | 71 |
| Alprazolam | Alprazolam | 204 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 52 |
| Ezetimibe | Ezetimibe | 157 | 44 |
| Azithromycin | Azithromycin | 148 | 121 |
| Montelukast Sodium | Montelukast Sodium | 147 | 46 |
| Metformin Hcl | Metformin Hcl | 138 | 42 |
| Mounjaro | Tirzepatide | 137 | 19 |
| Synthroid | Levothyroxine Sodium | 137 | 39 |
| Bupropion Xl | Bupropion Hcl | 129 | 35 |
| Farxiga | Dapagliflozin Propanediol | 128 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Allopurinol | Allopurinol | 106 | 26 |
| Jardiance | Empagliflozin | 105 | 26 |
| Sertraline Hcl | Sertraline Hcl | 105 | 30 |
| Famotidine | Famotidine | 100 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 87 |
| Meloxicam | Meloxicam | 91 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 26 |
| Gabapentin | Gabapentin | 85 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Eliquis | Apixaban | 78 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 29 |
| Valsartan | Valsartan | 78 | 23 |
| Atenolol | Atenolol | 76 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 74 | 25 |
| Benazepril Hcl | Benazepril Hcl | 73 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Ozempic | Semaglutide | 71 | 15 |
| Trazodone Hcl | Trazodone Hcl | 70 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 16 |
| Lorazepam | Lorazepam | 57 | 21 |
| Potassium Chloride | Potassium Chloride | 57 | 21 |
| Furosemide | Furosemide | 55 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 14 |
| Celecoxib | Celecoxib | 49 | 18 |
| Diazepam | Diazepam | 47 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Temazepam | Temazepam | 43 | suppressed |
| Torsemide | Torsemide | 43 | 15 |
| Carvedilol | Carvedilol | 41 | 12 |
| Rybelsus | Semaglutide | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Mupirocin | Mupirocin | 40 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 40 | 28 |
| Cefdinir | Cefdinir | 38 | 35 |
| Irbesartan | Irbesartan | 38 | 11 |
| Methocarbamol | Methocarbamol | 38 | 31 |
| Clonazepam | Clonazepam | 37 | 19 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 21 |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Gemtesa | Vibegron | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Cephalexin | Cephalexin | 17 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Finasteride | Finasteride | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $933.05 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VYEPTI, Wegovy, ZEPBOUND, Zypitamag | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error